At present, Chinese medical device companies are facing unprecedented regulatory challenges. With the strengthening of global medical device regulatory agencies, the difficulty and cost of certification have increased. Higher requirements have been put forward in product risk management, performance and safety standards, clinical evaluation before market launch, and post market vigilance and supervision, bringing new challenges to relevant companies entering the European Union.